Tilray Reports Record $257 Million Quarterly Revenue Amid Declining Cannabis Sales
Tilray Brands (TLRY) reported record first-quarter fiscal 2027 revenue of $257.1 million, a 23% increase year-over-year, driven largely by its beverage and pharmaceutical distribution segments. While gross profit rose to $77.5 million with improved margins, the company's core cannabis business saw a 13% decline in net revenue, primarily due to significant weakness in the Canadian adult-use and medical markets. The company is successfully diversifying; beverage revenue surged 82% to $101.5 million following the BrewDog acquisition, now accounting for 39% of total revenue. However, this growth has not yet translated into bottom-line profitability, as Tilray reported a quarterly net loss of approximately $40 million and negative free cash flow of $27.4 million.
Tickers: $TLRY
Topics: beverage sector cannabis industry earnings report pharmaceutical distribution revenue growth